Wall Street's expectations appear to be that the company's slower-than-average growth is going to continue over the next few years. The problem in Starboard's view is that Kenvue's skin and beauty ...

Kenvue owns a strong portfolio of household brands like Tylenol, Benadryl and Band-Aid. Read why I continue to rate KVUE ...

Kenvue is guiding for $1.10 to $1.20 in 2024 earnings per share and 2% to 4% organic sales growth. If it achieves the ...

On Oct. 21, news broke that Starboard Value took a position in Kenvue. The firm thinks there is an opportunity to improve ...

Sanofi and CD&R entered into exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.

The growth rate of the consumer healthcare business could accelerate now that an activist investor is involved.

Me CEO Anne Wojcicki continues to maintain a strong outlook despite recent high-profile stumbles. “We are a long-term company ...

(Reuters) -Hedge fund Starboard Value has taken a stake in Kenvue, the consumer products company that makes Band-Aid, ...

Starboard Chief Executive Jeff Smith said that Kenvue, the Tylenol-maker spun out from Johnson & Johnson, should drill down on fixing its underperforming skin health and beauty segment, which he ...

Recent health news includes Amgen's launch of an Eylea biosimilar in the U.S., Slovakia's bird flu outbreak, and China's ...

Starboard Value LP Chief Executive Officer Jeffrey Smith said there has been at least $20 billion in value destruction at drugmaker Pfizer Inc., which he admonished for failing to deliver on a ...

Financial writer analyzes activist hedge fund CEO's call for Kenvue to revamp skincare, health, and beauty segments for ...